Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Pfizer seeks UK approval for use of COVID-19 vaccine in teenagers

05/11/2021 | 05:12pm EDT

* Pfizer submits data from trials in 12- to 15-year olds

* EU also reviewing shot for same group

* Canada, U.S. have started vaccinating children with Pfizer shot

May 12 (Reuters) - Pfizer is seeking British approval for the use of its COVID-19 vaccine among 12- to 15-year olds and has submitted data to the health regulator, a company representative said on Tuesday, paving the way for inoculation of adolescents in the country.

The vaccine, developed along with Germany's BioNTech , has already been approved in the United States and Canada for use against COVID-19 infections in children and young adults.

"I can confirm we've submitted data on the efficacy of the vaccine in 12 to 15 year olds for review by U.K. MHRA," an official for the U.S. drugmaker told Reuters, referring to the Medicines and Healthcare products Regulatory Agency.

Health officials are banking on vaccines to end the pandemic, but are worried that some parents will be hesitant in vaccinating their children due to fears of potential side effects and long-term risks. Kids under 12 have so far been less susceptible to COVID-19.

The drugmakers have said their shot is safe, effective and produced robust antibody responses in children as young as 12 years of age.

The vaccine, which uses mRNA technology to deliver instructions to the human body to build immunity against the illness, is also being tested in children aged two to 11, with safety and efficacy data expected in September, Pfizer has said.

Although other drugmakers, including AstraZeneca, Moderna and Johnson & Johnson <J&J>, are working on vaccines for children, Pfizer and BioNTech have managed to steal a march.

Pfizer's vaccine, branded Comirnaty, is also under an EU review for use in children aged 12 to 15 years, with the head of the region's medicines regulator saying an approval could come as early as end-May.

The Telegraph earlier reported on the British review, saying the vaccine was likely to be approved before the end of July.

The MHRA did not immediately respond to a Reuters request for comment. (Reporting by Pushkala Aripaka, Nandakumar D and Derek Francis in Bengaluru, Alistair Smout in London; Editing by Richard Pullin, Stephen Coates and Anil D'Silva)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.29% 8408 Delayed Quote.14.47%
MODERNA, INC. 4.54% 208.24 Delayed Quote.90.67%
All news about MODERNA, INC.
04:44pMODERNA  : Canadians encouraged to see mRNA shots as interchangeable as more 2nd..
AQ
02:41pDow leads the way in broad Wall Street rally
RE
12:33pMODERNA  : U.S. directs millions of COVID-19 shots to Latin America, Africa, Asi..
RE
12:04pMODERNA  : WHO setting up hub to make COVID-19 vaccines in South Africa
RE
12:04pMODERNA  : WHO setting up hub to make COVID-19 vaccines in South Africa
RE
12:00pMODERNA  : White House lays out plan to share remaining 55 mln U.S. COVID-19 sho..
RE
11:56aMODERNA  : Boosts COVID-19 Vaccine Production Capacity to Triple Output in 2022
MT
11:53aWall St bounces back on boost from banks, industrials
RE
11:49aWho chief scientist says talking to pfizer and moderna about their involvemen..
RE
10:43aBionity - Mix-and-match vaccines generate a particularly strong immune respon..
AQ
More news
Financials (USD)
Sales 2021 18 664 M - -
Net income 2021 10 397 M - -
Net cash 2021 11 520 M - -
P/E ratio 2021 8,08x
Yield 2021 -
Capitalization 79 980 M 79 980 M -
EV / Sales 2021 3,67x
EV / Sales 2022 3,72x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 168,87 $
Last Close Price 199,19 $
Spread / Highest target 23,5%
Spread / Average Target -15,2%
Spread / Lowest Target -58,3%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.90.67%79 980
LONZA GROUP AG14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367
HANGZHOU TIGERMED CONSULTING CO., LTD14.49%24 102